Scout Investments Inc. lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 7.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 152,672 shares of the company’s stock after selling 12,102 shares during the period. Scout Investments Inc. owned 0.39% of Omnicell worth $10,977,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Bank of Montreal Can purchased a new stake in shares of Omnicell during the 2nd quarter worth approximately $102,000. Virtu Financial LLC bought a new position in Omnicell in the 2nd quarter worth approximately $204,000. First Republic Investment Management Inc. bought a new position in Omnicell in the 2nd quarter worth approximately $226,000. Jane Street Group LLC bought a new position in Omnicell in the 1st quarter worth approximately $237,000. Finally, WINTON GROUP Ltd bought a new position in Omnicell in the 1st quarter worth approximately $279,000. Institutional investors own 98.80% of the company’s stock.
OMCL opened at $65.27 on Thursday. The company has a market capitalization of $2.82 billion, a P/E ratio of 362.61, a price-to-earnings-growth ratio of 3.55 and a beta of 0.98. Omnicell, Inc. has a 12 month low of $39.75 and a 12 month high of $73.00. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.31.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 26th. The company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.07. The company had revenue of $188.70 million during the quarter, compared to the consensus estimate of $188.80 million. Omnicell had a net margin of 5.27% and a return on equity of 5.88%. Omnicell’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period last year, the firm earned $0.31 EPS. On average, equities analysts expect that Omnicell, Inc. will post 1.35 earnings per share for the current year.
In other Omnicell news, EVP Jorge R. Taborga sold 17,644 shares of the firm’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $58.77, for a total value of $1,036,937.88. Following the completion of the transaction, the executive vice president now directly owns 44,973 shares of the company’s stock, valued at approximately $2,643,063.21. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director James T. Judson sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $58.76, for a total transaction of $293,800.00. Following the completion of the transaction, the director now directly owns 39,952 shares of the company’s stock, valued at $2,347,579.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,478 shares of company stock valued at $2,812,339. Insiders own 3.71% of the company’s stock.
OMCL has been the subject of several analyst reports. TheStreet raised shares of Omnicell from a “c+” rating to a “b” rating in a report on Friday, July 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Omnicell in a report on Thursday, July 26th. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. Benchmark initiated coverage on shares of Omnicell in a report on Friday, June 29th. They issued a “buy” rating and a $63.00 price objective for the company. Finally, Craig Hallum raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a report on Friday, July 27th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $66.40.
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
See Also: Understanding the different types of bonds
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.